Key result
COVID-19 myocarditis presents primarily as a post-infection complication managed largely with supportive care.
Why the study?
The diagnosis of myocarditis in COVID-19 poses many challenges.
This review summarizes the pathophysiology, diagnosis, and supportive treatment strategies for COVID-19-related and post-vaccination myocarditis.
Supports continued reliance on supportive care for COVID-19 myocarditis; leaves open prospective studies on post-vaccination cases.
Myocarditis is a rare inflammatory disease affecting the myocardium and is caused by a variety of factors – medications, toxins, viruses and other processes that can include the heart muscle. It presents with multiple symptoms and can lead to heart failure and in some cases even sudden death. The diagnosis of myocarditis especially in COVID-19 poses many challenges. In regards to SARS-CoV-2 the post-infection myocarditis is more common, however there were some cases of post-vaccination myocarditis present. Treatment strategies are primarily supportive and focused on battling the symptoms. In this article we focused on research about pathophysiology, clinical presentation, diagnosis, treatment and long-term effects of COVID-19 on the heart.
No takes yet. Share an insight, caveat, or question.
Walkowski et al. (2025) conducted a review in Myocarditis in COVID-19. COVID-19-related myocarditis is primarily a post-infection complication, though post-vaccination cases occur, with treatment strategies remaining largely supportive.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: